Quantitative levels of aripiprazole parent drug and metabolites in urine

Joseph Patrick McEvoy, Robert A. Millet, Kenneth Dretchen, Ayodele A. Morris, Michael J. Corwin, Peter F Buckley

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The aim of this study is to assess urine levels of aripiprazole and metabolites among patients receiving steady-state dosing of aripiprazole. Methods: One hundred fifty adults, judged compliant with a stable aripiprazole regimen, had observed dosing for 5 consecutive days. Urine specimens, obtained on days 1, 4, and 5, were analyzed for pH, creatinine, specific gravity, and for aripiprazole, OPC3373, and dehydroaripiprazole. Linear regression was used to assess the association between unadjusted urine levels of each drug/metabolite and dose taken, and linear stepwise multiple regression was performed to identify variables that added to the explanation of the variance. Results: OPC3373 was found in 97 % of urine samples, whereas unchanged aripiprazole and dehydroaripiprazole were found in only 58 and 39 % of samples, respectively. Variance in urine metabolite levels accounted for by medication dose was relatively low for each individual drug/metabolite, r 2 only 0.13 to 0.23. However, when OPC3373 was adjusted for age, weight, sex, and urine creatinine values, the r 2 improved to 0.63, and further improved to 0.70, when height, urine specific gravity, and the presence of dehydroaripiprazole were added in a stepwise multiple regression model. Conclusions: Unadjusted urine levels of aripiprazole and metabolites are not strongly related to aripiprazole dosing, however, accounting for key variables yields a strong relationship between measurable urine parameters and dose taken. By defining the expected range of adjusted urine levels for each dose, the potential exists for a clinical test to identify partially nonadherent individuals who would not have been identified by conventional "present vs. absent" urine drug testing.

Original languageEnglish (US)
Pages (from-to)4421-4428
Number of pages8
JournalPsychopharmacology
Volume231
Issue number23
DOIs
StatePublished - Jan 1 2014

Fingerprint

Parents
Urine
Pharmaceutical Preparations
Specific Gravity
Creatinine
Aripiprazole
Linear Models
Weights and Measures
dehydroaripiprazole

Keywords

  • Aripiprazole
  • Dehydroaripiprazole
  • OPC3373
  • Urine drug testing

ASJC Scopus subject areas

  • Pharmacology

Cite this

McEvoy, J. P., Millet, R. A., Dretchen, K., Morris, A. A., Corwin, M. J., & Buckley, P. F. (2014). Quantitative levels of aripiprazole parent drug and metabolites in urine. Psychopharmacology, 231(23), 4421-4428. https://doi.org/10.1007/s00213-014-3781-1

Quantitative levels of aripiprazole parent drug and metabolites in urine. / McEvoy, Joseph Patrick; Millet, Robert A.; Dretchen, Kenneth; Morris, Ayodele A.; Corwin, Michael J.; Buckley, Peter F.

In: Psychopharmacology, Vol. 231, No. 23, 01.01.2014, p. 4421-4428.

Research output: Contribution to journalArticle

McEvoy, JP, Millet, RA, Dretchen, K, Morris, AA, Corwin, MJ & Buckley, PF 2014, 'Quantitative levels of aripiprazole parent drug and metabolites in urine', Psychopharmacology, vol. 231, no. 23, pp. 4421-4428. https://doi.org/10.1007/s00213-014-3781-1
McEvoy, Joseph Patrick ; Millet, Robert A. ; Dretchen, Kenneth ; Morris, Ayodele A. ; Corwin, Michael J. ; Buckley, Peter F. / Quantitative levels of aripiprazole parent drug and metabolites in urine. In: Psychopharmacology. 2014 ; Vol. 231, No. 23. pp. 4421-4428.
@article{2acd3cb2e98c44208dd95753f9595741,
title = "Quantitative levels of aripiprazole parent drug and metabolites in urine",
abstract = "Objective: The aim of this study is to assess urine levels of aripiprazole and metabolites among patients receiving steady-state dosing of aripiprazole. Methods: One hundred fifty adults, judged compliant with a stable aripiprazole regimen, had observed dosing for 5 consecutive days. Urine specimens, obtained on days 1, 4, and 5, were analyzed for pH, creatinine, specific gravity, and for aripiprazole, OPC3373, and dehydroaripiprazole. Linear regression was used to assess the association between unadjusted urine levels of each drug/metabolite and dose taken, and linear stepwise multiple regression was performed to identify variables that added to the explanation of the variance. Results: OPC3373 was found in 97 {\%} of urine samples, whereas unchanged aripiprazole and dehydroaripiprazole were found in only 58 and 39 {\%} of samples, respectively. Variance in urine metabolite levels accounted for by medication dose was relatively low for each individual drug/metabolite, r 2 only 0.13 to 0.23. However, when OPC3373 was adjusted for age, weight, sex, and urine creatinine values, the r 2 improved to 0.63, and further improved to 0.70, when height, urine specific gravity, and the presence of dehydroaripiprazole were added in a stepwise multiple regression model. Conclusions: Unadjusted urine levels of aripiprazole and metabolites are not strongly related to aripiprazole dosing, however, accounting for key variables yields a strong relationship between measurable urine parameters and dose taken. By defining the expected range of adjusted urine levels for each dose, the potential exists for a clinical test to identify partially nonadherent individuals who would not have been identified by conventional {"}present vs. absent{"} urine drug testing.",
keywords = "Aripiprazole, Dehydroaripiprazole, OPC3373, Urine drug testing",
author = "McEvoy, {Joseph Patrick} and Millet, {Robert A.} and Kenneth Dretchen and Morris, {Ayodele A.} and Corwin, {Michael J.} and Buckley, {Peter F}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00213-014-3781-1",
language = "English (US)",
volume = "231",
pages = "4421--4428",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "23",

}

TY - JOUR

T1 - Quantitative levels of aripiprazole parent drug and metabolites in urine

AU - McEvoy, Joseph Patrick

AU - Millet, Robert A.

AU - Dretchen, Kenneth

AU - Morris, Ayodele A.

AU - Corwin, Michael J.

AU - Buckley, Peter F

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: The aim of this study is to assess urine levels of aripiprazole and metabolites among patients receiving steady-state dosing of aripiprazole. Methods: One hundred fifty adults, judged compliant with a stable aripiprazole regimen, had observed dosing for 5 consecutive days. Urine specimens, obtained on days 1, 4, and 5, were analyzed for pH, creatinine, specific gravity, and for aripiprazole, OPC3373, and dehydroaripiprazole. Linear regression was used to assess the association between unadjusted urine levels of each drug/metabolite and dose taken, and linear stepwise multiple regression was performed to identify variables that added to the explanation of the variance. Results: OPC3373 was found in 97 % of urine samples, whereas unchanged aripiprazole and dehydroaripiprazole were found in only 58 and 39 % of samples, respectively. Variance in urine metabolite levels accounted for by medication dose was relatively low for each individual drug/metabolite, r 2 only 0.13 to 0.23. However, when OPC3373 was adjusted for age, weight, sex, and urine creatinine values, the r 2 improved to 0.63, and further improved to 0.70, when height, urine specific gravity, and the presence of dehydroaripiprazole were added in a stepwise multiple regression model. Conclusions: Unadjusted urine levels of aripiprazole and metabolites are not strongly related to aripiprazole dosing, however, accounting for key variables yields a strong relationship between measurable urine parameters and dose taken. By defining the expected range of adjusted urine levels for each dose, the potential exists for a clinical test to identify partially nonadherent individuals who would not have been identified by conventional "present vs. absent" urine drug testing.

AB - Objective: The aim of this study is to assess urine levels of aripiprazole and metabolites among patients receiving steady-state dosing of aripiprazole. Methods: One hundred fifty adults, judged compliant with a stable aripiprazole regimen, had observed dosing for 5 consecutive days. Urine specimens, obtained on days 1, 4, and 5, were analyzed for pH, creatinine, specific gravity, and for aripiprazole, OPC3373, and dehydroaripiprazole. Linear regression was used to assess the association between unadjusted urine levels of each drug/metabolite and dose taken, and linear stepwise multiple regression was performed to identify variables that added to the explanation of the variance. Results: OPC3373 was found in 97 % of urine samples, whereas unchanged aripiprazole and dehydroaripiprazole were found in only 58 and 39 % of samples, respectively. Variance in urine metabolite levels accounted for by medication dose was relatively low for each individual drug/metabolite, r 2 only 0.13 to 0.23. However, when OPC3373 was adjusted for age, weight, sex, and urine creatinine values, the r 2 improved to 0.63, and further improved to 0.70, when height, urine specific gravity, and the presence of dehydroaripiprazole were added in a stepwise multiple regression model. Conclusions: Unadjusted urine levels of aripiprazole and metabolites are not strongly related to aripiprazole dosing, however, accounting for key variables yields a strong relationship between measurable urine parameters and dose taken. By defining the expected range of adjusted urine levels for each dose, the potential exists for a clinical test to identify partially nonadherent individuals who would not have been identified by conventional "present vs. absent" urine drug testing.

KW - Aripiprazole

KW - Dehydroaripiprazole

KW - OPC3373

KW - Urine drug testing

UR - http://www.scopus.com/inward/record.url?scp=84922086859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922086859&partnerID=8YFLogxK

U2 - 10.1007/s00213-014-3781-1

DO - 10.1007/s00213-014-3781-1

M3 - Article

C2 - 25345737

AN - SCOPUS:84922086859

VL - 231

SP - 4421

EP - 4428

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 23

ER -